egfr tyrosine kinase

Gefitinib (ZD1839) is an EGFR first-generation inhibitor with oral activity that inhibits the EGFR 19 Del and L858R mutations. Gefitinib has antitumor activity and is used for the treatment of EGFR-mutated non-small-cell lung cancers. Gefitinib administration RESULTS in the development of the EGFR C797S resistance mutation.

Tannic acid (Gallotannic acid) is a novel hERG channel blocker.

Halociline, a derivative of alkaloids that can be isolated from the marine fungus Penicillium griseofulvum, targets MAPK1, MMP-9, and PIK3CA in gastric cancer cells. This action is potentially mediated by diverse pathways, including cancer, lipid metabolism, atherosclerosis, and EGFR tyrosine kinase inhibitor resistance. Halociline possesses antimicrobial, antioxidant, and biofilm inhibitory activities [1] [2].

1,5-Dihydroxyxanthone exhibits the epidermal growth factor receptor (EGFR) -tyrosine kinase inhibitory activity, with the IC50 value of 90.34 nM. It may have anticholinesterase activity on acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) enzym

lavendustin A (RG-14355) is a potent, cell-permeable inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase.